by Mark Curtis | Feb 19, 2015
. Welcome to your Update from the Clinic for the month of January. Pluristem and OncoMed reported preliminary efficacy data from early-stage trials, while the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) granted a number of Orphan Drug...
by David Kent | Feb 9, 2015
> This article is the second in a series about the human capital created by the Network of Centre of Excellence known as the Stem Cell Network (SCN), which was created in 2001, will wind down the majority of it’s activities this year. The first article focused on...
by David Kent | Feb 2, 2015
> As many of our readers are aware, the Network of Centre of Excellence known as the Stem Cell Network (SCN), which was created in 2001, will wind down the majority of it’s activities this year. I have been a trainee/alumnus since the start of my PhD in 2003 and...
by James Smith | Jan 26, 2015
With contributions from David Brindley . Cell-based treatments are being developed and marketed for a variety of indications: from rare orphan diseases like graft versus host disease (GvHD), to blockbuster conditions like diabetes and cardiovascular disease that...
by Stacey Johnson | Jan 20, 2015
. Before you read my blog, I recommend that you first read Sara Nolte’s blog “Bad luck, bad science, or bad reporting?” In it, Sara does an excellent job explaining and commenting on Drs. Cristian Tomasetti’s and Bert Vogelstein’s study “Variation in cancer risk among...
by Sara M. Nolte | Jan 19, 2015
. If you’ve been on the Internet at all in 2015, you’ve probably stumbled across headlines like “Two-thirds of cancers are due to ‘back luck,’ study finds” (CBSNews), “Most cancers are caused by bad luck not genes or lifestyle say scientists” (The Telegraph), “Cause...
Comments